Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

5

6

7

8

9

10

11

12

13

14

15

16

17

18

>

>|

Found 72 Matches

MefenamicAcid_Dapagliflozin_V15R1_Pfizer_20220726
Mefenamic acid and dapagliflozin/healthy volunteer. This workspace simulates the UGT mediated DDI after multiple dose administration of UGT inhibitor mefenamic acid. The workspace shows Dapaglifazin as substrate of UGTA9 and UGT2B7. Mefenamic Acid is used in the inhibitor position and Ki values against UGT1A9 and UGT2B7 are included in the workspace.
Pitavastatin_V17R1_ASTAR_20190730
The submitted compound file for Pitavastatin uses ADAM, Full PBPK method 2, enzyme kinetics for metabolism and transporter kinetics for intestinal absorption, permeability limited liver model and MechKiM model. Tissue : Plasma partition coefficients have been modified to include data obtained from rat distribution studies. It has been used together with the unmodified Sim-Healthy Volunteer library file. https://www.altex.org/index.php/altex/article/view/1215
Rosuvastatin_V17R1_ASTAR_20190724
The submitted compound file for Rosuvastatin uses ADAM, Full-PBPK method 2, enzyme kinetics for metabolism and transporter kinetics for the permeability limited liver model and MechKim model. Tissue : Plasma partition coefficients have been modified to include data obtained from rat distribution studies. It has been used together with the unmodified Sim-Healthy Volunteer library file. https://www.ncbi.nlm.nih.gov/pubmed/31079160

Brand Name(s) include: N/A

Disease: Malaria

Drug Class: Antimalarials

Date Updated: June 2021

Related Files: Amodiaquine (parent drug)

The model at-a-glance

  Absorption Model

  • N/A

  Volume of Distribution

  • Minimal PBPK (Method 2)

  Route of Elimination

  • CLPO (non-specific) and renal clearance

  Perpetrator DDI

  • CYP2D6

  Validation

  • Simulations based on 1 clinical study describing multiple dose exposure of DHEA and 1 DDI study where formation of DHEA was the victim of a CYP2C9 mediated DDI were both within 1.5-fold of the observed values.

  Limitations

  • Clinical data has not been used to verify DEAQ as a perpetrator of CYP2D6-mediated DDIs

  Updates in V19

  • Updated DEAQ Ki for CYP2D6

 

|<

<

5

6

7

8

9

10

11

12

13

14

15

16

17

18

>

>|